Organigram Holdings Inc. - Common Shares (OGI)
1.0800
+0.0100 (0.93%)
Organigram Holdings Inc. is a Canadian licensed producer of cannabis, focused on the development and cultivation of high-quality marijuana products for both medical and recreational markets
The company operates state-of-the-art facilities that utilize advanced technology and sustainable practices to grow and produce a variety of cannabis strains, including dried flower and cannabis oils. Organigram is committed to innovation in product development, creating a wide range of cannabis-infused products such as edibles, beverages, and vape oils. With a strong emphasis on compliance, quality control, and consumer education, Organigram aims to be a leading player in the evolving cannabis industry while promoting responsible use and supporting community initiatives.

British American Tobacco finalizes a C$124.6M investment in Organigram, reinforcing big tobacco's stake in cannabis.
Via Benzinga · March 5, 2025

OGI earnings call for the period ending December 31, 2024.
Via The Motley Fool · February 11, 2025

Organigram's Q1 FY25 sales hit C$66.8M. Net revenue rose 17%, and adjusted EBITDA improved to C$1.4M. Cash position set to reach C$113M.
Via Benzinga · February 11, 2025

DEA judge orders agency to respond to allegations of opposing marijuana rescheduling and improper communication with opponents. Cannabis stocks declined in 2024 due to concerns about DEA review.
Via Benzinga · January 8, 2025

Via Benzinga · January 1, 2025

OGI earnings call for the period ending September 30, 2024.
Via The Motley Fool · December 18, 2024

Organigram's Q4 sales hit $31.22 million, boosted by recreational and international growth, with adjusted gross margin improving to 37% of net revenue.
Via Benzinga · December 18, 2024

Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI) has announced the acquisition of 100% of Motif Labs Ltd. for CA$90 million ($64 million), comprising of CA$50 million in cash and CA$40 million in Organigram common shares, based on a 30-day trading VWAP of $2.321 on the TSX. An additional CA$10 million contingent consideration is payable in shares, conditional on achieving a share price above $3.2203 within 12 months. The deal is financed through Organigram's cash reserves.
Via Benzinga · December 6, 2024

Beyond Canada, this global cannabis company is focused on its international business, particularly in Germany, Australia, and the UK.
Via Benzinga · December 5, 2024

Decibel, a leading Canadian pre-roll franchise, may trade closer to larger market-cap cannabis stocks, according to analyst Pablo Zuanic.
Via Benzinga · December 4, 2024

Cannabis stocks rally on prediction of Trump descheduling marijuana; MSOS leads gains with a 15% surge, followed by Cronos at nearly 13%.
Via Benzinga · November 12, 2024

Following Trump's presidential election victory, the cannabis sector took a sharp downturn. Here's a summary of what happened today.
Via Benzinga · November 6, 2024

Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies.
Via Benzinga · October 29, 2024

Cannabis stocks rally as Canopy Growth, Aurora Cannabis, SNDL, and OrganiGram show positive momentum. We look at resistance levels...
Via Benzinga · October 25, 2024

Experts from the Benzinga Cannabis Capital Conference examined the profitability and growth prospects across global marijuana markets.
Via Benzinga · October 14, 2024

Via Benzinga · September 26, 2024
Our Conservative Cannabis Stocks Portfolio has outperformed our Canadian Cannabis LP Stocks Portfolio by more than a 3 to 1 margin on an annual basis. As such, our conservative cannabis portfolio is just that - a conservative cannabis investment.
Via Talk Markets · September 16, 2024
The Canadian Cannabis LP Stocks Portfolio was up +6% last week from a 10% decline w/e Sept. 6th as the negative sentiment waned surrounding the DEA's announcement that it would be having a December 2nd hearing to consider additional opinions
Via Talk Markets · September 15, 2024